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Abstract
Paeonia lactiﬂora Pall. (Ranunculaceae) root and Sinomenium acutum Rehder and Wilson (Menispermaceae) stem are two herbs widely
used in Chinese medicine to treat rheumatoid arthritis. While, in theory, either herb could be used alone, in practice, Chinese medicine
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dractitioners prescribe them together. Studies on pharmacokinetic interaction between the active constituents of these two herbs (paeoniflorin
nd sinomenine, respectively) provide empirical evidence to support their clinical practice. A single dose of paeoniflorin (150 mg/kg) alone and
ith sinomenine hydrochloride (90 mg/kg) was administered by gastric gavage to unrestrained conscious male Sprague–Dawley rats (n= 6,
50–300 g). Blood samples were collected periodically via a jugular vein before and after dosing from 10 min to 12 h. A high-performance liquid
hromatographic (HPLC) assay was developed to determine the plasma concentrations of paeoniflorin. Non-compartmental pharmacokinetic
rofiles were constructed by using the software PK Solutions 2.0. The pharmacokinetic parameters were compared using unpaired Student
-test. After co-administration of sinomenine, the peak plasma concentration of paeoniflorin was elevated (P< 0.01), the peak time was delayed
P< 0.01), the AUC0–t was increased (P< 0.001), the mean residence time (MRT) was prolonged (P< 0.01), the CL was decreased (P< 0.01)
nd the Vd was reduced (P< 0.05). These results indicate that sinomenine hydrochloride at 90 mg/kg significantly improved the bioavailability
f paeoniflorin in rats.
2005 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Paeoniflorin is a bioactive monoterpene glucoside (Fig. 1)
resenting in the root of Paeonia lactiﬂora Pall. (family Ra-
unculaceae), which has been widely used to treat inflam-
ation and arthritic conditions according to the traditional
hinese medical system. The therapeutic effects of the herb
nd its active component, paeoniflorin, have been confirmed
y experimental pharmacological investigations (Takagi and
arada, 1969a,b). However, previous pharmacokinetic stud-
es have shown that paeoniflorin has a poor absorption rate,
nd thus a very low bioavailability (3–4%) when adminis-
∗ Corresponding author. Tel.: +852 3411 5308; fax: +852 3411 5317.
E-mail address: Profchan@hkbu.edu.hk (K. Chan).
tered orally. This is probably due to limited transportation
of paeoniflorin across the gastrointestinal mucosa (Takeda et
al., 1995, 1997). In Mainland China, the total glucosides of
Paeonia lactiﬂora Pall. (TGP) comprising more than 70% of
paeoniflorin, has been approved by the State Food and Drugs
Administration of China for the clinical application in treat-
ing rheumatic and arthritic diseases as a patented botanical
drug (Zhao et al., 1997). While the drug is useful, neverthe-
less, the low bioavailability of paeoniflorin might be restrict-
ing its therapeutic efficacy. Therefore, this investigation aims
to use the pharmacokinetic profile of paeoniflorin to find a
way to improve its bioavailability and thereby enhance its
therapeutic efficacy.
In treating arthritis, Chinese medicine practitioners usu-
ally include both the root of Paeonia lactiﬂora and the
378-8741/$ – see front matter © 2005 Elsevier Ireland Ltd. All rights reserved.
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Nomenclature
AUC0–∞ area under concentration–time curve from
zero up to infinite time
AUC0–t area under concentration–time curve from zero
up to a definite time t
CL total clearance
Cmax maximum plasma concentration
Frel relative bioavailability
HPLC high-performance liquid chromatography
MRT mean residence time
R.S.D. relative standard deviation
t1/2 A phase half-life of absorption phase
t1/2 D/A phase half-life of distribution phase
t1/2 E phase half-life of elimination phase
tmax time to reach maximum plasma concentration
TGP total glucosides of Paeonia lactiﬂora Pall.
Vd volume of distribution
stem of Sinomenium acutum Rehder and Wilson (fam-
ily Menispermaceae) in their medical prescriptions. This
clinical practice suggests that there might be synergic
effects between the herbs (Wong and Wu, 1936). Pre-
vious work on the Chinese medicinal herb Sinomenium
acutum demonstrated that the alkaloid sinomenine is one
of the main active components of the plant (Tai and
Hopkins, 1998). Sinomenine (7,8-didehydro-4-hydroxy-3,7-
dimethoxy-17-methylmorphinan-6-one; Fig. 2) has been
demonstrated to significantly inhibit inflammatory reactions
caused by various phlogistic agents (Irino, 1958; Cheng et
al., 1964; Huo and Che, 1989). The therapeutic efficacy of
sinomenine was also confirmed in patients with rheumatoid
arthritis (Ke and Xiu, 1986; Shi et al., 1986). Studies in our
previous work have revealed that the alkaloid has marked
effects in inhibiting the proliferation of mouse spleen cells,
human peripheral blood mononuclear cells as well as rat syn-
ovial fibroblasts, the synthesis of proinflammatory mediators
of prostaglandin E2 and leukotriene C4 and the production of
nitric oxide by macrophages (Liu et al., 1994a,b, 1999). It has
also been shown to significantly ameliorate arthritic patholo-
Fig. 2. Chemical structure of sinomenine.
gies in adjuvant arthritis rats (Liu et al., 1999). Studies on the
pharmacokinetics of sinomenine using technologies of mi-
crodialysis and a hepato-duodenal shunt probe in rats demon-
strated that sinomenine undergoes active hepatobiliary elimi-
nation; this process might be regulated by P-glycoprotein and
probably involves P450 (Tsai and Wu, 2003). Therefore, in
the present study we chose to investigate the possible influ-
ences of sinomenine on paeoniflorin by pharmacokinetics to
see if interaction between these two constituents was respon-
sible for the enhancement observed in using the two herbs
together in clinical practice.
2. Materials and methods
2.1. High-performance liquid chromatography analysis
The HPLC system consisted of an Agilent quater-
nary HPLC model HP 1100 series (Hewlett-Packard, Palo
Alto, CA, USA), fitted with an Altima C18 column
(250 mm× 4.5 mm, 5m). The mobile phase used was wa-
ter:acetonitrile (86:14), filtered through a 0.45m Millipore
filter (Millipore, Hong Kong). The flow-rate was maintained
at 1 ml/min, and the detection was performed at a wavelength
of 231 nm under constant temperature (25± 0.1 ◦C).
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The reference standards of paeoniflorin and sinomenine
ydrochloride (≥98%) were purchased from the State Insti-
ute for the Control of Pharmaceutical and Biological Prod-
cts of China. Pentoxifylline, the internal standard for paeoni-
orin, was purchased from Sigma (St. Louis, MO, USA).
cetonitrile and perchloric acid were obtained from Merck
Darmstadt, Germany).
.3. Animals
Male Sprague–Dawley rats weighing 250–300 g were pur-
hased from the Laboratory Animal Services Center of the
hinese University of Hong Kong. The animals were housed
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in different cages (five animals per cage) and acclimated in
the laboratory for at least one-week prior to testing. Before
experiments the animals were fasted for 12 h with water ad
libitum, and maintained at 21 ◦C temperature with 60% rela-
tive humidity and a 12 h light/12 h dark cycle. After surgery,
rats were housed individually in metabolite cages for one-
week recovery and underwent pharmacokinetic treatment ac-
cording to a jugular-catheterized rat model (Thrivikraman et
al., 2002). All procedures involving animals and their care
were carried out according to the regulations of the Com-
mittee on the Use of Human & Animal Subjects in Teach-
ing and Research of Hong Kong Baptist University and
Health Department of Hong Kong Special Administrative
Region.
2.4. Surgery
Silicone medical grade tubing 100 mm long (Silastic Cat.
No. 602-155; Dow Corning, Midland, MI, USA) with two
stoppers made of medical adhesive silicone (Silastic Cat. No.
801; Dow Corning) was used. For insertion of the catheter in
the sinus venosus, the length of the tip of the catheter to the
first stopper was set at 26 mm (Harms and Ojeda, 1974).
Rats were anesthetized by intraperitoneal administration
of a mixture of 1.0 ml acepromazine maleate (10 mg/ml),
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replaced by a collection syringe the desired amount (0.2 ml)
of blood was taken. Next, the collection syringe was removed
and replaced with a heparinized syringe. Blood was gently
rinsed from the catheter by flushing with the same volume of
heparinized saline (20 units/ml) to replace the loss volume of
blood a plug was inserted in the catheter. Finally, the blood
was expelled from the collection syringe into a heparinized
1.5 ml micro-centrifuge tube.
In each of the experiments, one rat was administered
with paeoniflorin alone, while another was administered
with paeoniflorin plus sinomenine hydrochloride. Both com-
pounds were prepared as an aqueous solution and admin-
istered orally to the fasted rats. For the co-administration
protocol, paeoniflorin was first administered at the dosage
of 150 mg/kg body weight, and then, immediately following,
sinomenine was administered at the dosage of 90 mg/kg body
weight.
After administration, jugular vein blood samples were col-
lected (0.2 ml) from the rats into heparinized 1.5 ml micro-
centrifuge tubes at the following time intervals: 0, 10, 20,
30, 45, 60, 80, 100, 120, 150, 180, 240, 300, 360, 540 and
720 min. Data from these samples were used to construct
pharmacokinetic profiles by plotting drug concentrations ver-
sus times.
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flml sterile water, 2.5 ml ketamine hydrochloride and 2.5 ml
ylazine hydrochloride in a sealed vial at a dosage of
25l/100 g of body weight. A longitudinal skin incision
as made over the area where the right external jugular vein
assed dorsal to the pectoralis major muscle. The catheter,
lled with 20 units/ml heparinized physiologic saline, was
ut into the tight jugular vein and then advanced into the si-
us venosus. The catheter was inserted up to the first silicone
topper and anchored in place by suturing the stopper to mus-
le. The free end of the catheter was passed under the skin of
he dorsum of the neck just caudal to the ears and attached to
he skin, together with a metal spring, which was covered with
VC tubing for protection of the outer part of the catheter.
inally, the catheter was filled with 500 units/ml heparinized
aline, and a plug was inserted in the free end of the catheter
Cocchetto and Bjornsson, 1983; Yoburn et al., 1984; NRC,
996; Kohn et al., 1997; Remie, 2000; Thrivikraman et al.,
000).
.5. Drug administration and blood sampling
Catheterized rats were left to recover from surgery in in-
ividual metabolite cages for at least 7 days. Before exper-
ments, three types of 1 ml syringes namely, flush syringe,
ollection syringe and heparinized syringe were prepared.
fter administration of the test compounds, blood samples
ere, firstly, drawn from the catheter using a flush syringe
tted with 27-gauge needle until a small amount of blood ap-
eared in the needle bulb, and then the heparin solution was
emoved from the catheter together with the first sampling of
0–50l blood. Next, the flushing syringe was removed and.6. Preparation of plasma samples
Each collected blood sample was immediately transferred
nto a heparinized 1.5 ml micro-centrifuge tube and cen-
rifuged at 8000 rpm for 6 min at room temperature. The
esulting plasma (50l) was then mixed with 50l 4.5%
erchloric acid aqueous solution and 50l internal standard
pentoxifylline in water 4.5g/ml) by vortex for 5 min. The
enatured protein precipitate was separated by centrifuga-
ion at 13,000 rpm for 10 min at room temperature. An 80l
olume supernatant was injected into the HPLC system for
nalysis. For recovery and precision determination of paeoni-
orin in plasma, the same procedures for handling the blood
amples were used.
.7. Calibration curve
A calibration curve was constructed based on the HPLC
nalysis of blank rat plasma spiked with various concentra-
ions (0.22, 0.45, 0.89, 1.78, 3.55, 7.10 and 10.65g/ml) of
aeoniflorin, together with a fixed amount of pentoxifylline
4.5g/ml). The various concentrations of paeoniflorin in
he plasmas were calculated from the values of peak areas
y using the equation for linear regression obtained from the
alibration curve.
.8. Recovery
Blank rat plasma samples were spiked with four different
oncentrations (0.15, 0.59, 4.73 and 7.10g/ml) of paeoni-
orin. After preparation of the plasma samples, fixed amounts
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of internal standard (pentoxifylline) were added to the plasma
for normalization. The resulting peak areas were compared
with those standards carried in distilled water so as to calcu-
late the recovery values.
2.9. Precision assay
The precision of the test was determined by triplicate anal-
yses of plasma samples (n= 3) spiked with four different con-
centrations (0.15, 0.59, 4.73 and 7.10g/ml) of paeoniflorin.
To determine intra-daily variances, the assays were carried
out on the same samples at three time intervals during one
day. Inter-daily variances were also determined by assaying
the spiked samples over three consecutive days. Relative stan-
dard deviations (R.S.D.) were calculated from these sampled
values of paeoniflorin.
2.10. Pharmacokinetic analysis
All data were subsequently processed by the pharmacoki-
netic software, PK Solutions 2.0 (Summit Co., USA). The
non-compartmental pharmacokinetic parameters of half-life
(t1/2), mean residence time (MRT), area under the plasma
concentration–time curve (AUC), clearance (CL) and vol-
ume of distribution (Vd) were calculated based on moment
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Fig. 3. Chromatograms of paeoniflorin in rat plasma. (A) Plasma sample
obtained from rat at 45 min after oral co-administration of paeoniflorin plus
sinomenine together spiked with internal standard (pentoxifylline); (B) blank
plasma before oral administration spiked with internal standard (pentoxi-
fylline) and (C) blank plasma spiked with paeoniflorin (4.73g/ml) alone
and internal standard pentoxifylline (4.5g/ml).
amount ratio of paeoniflorin to pentoxifylline in plasma and
Y is the area ratio of paeoniflorin to pentoxifylline) was ob-
tained.
3.3. Recovery test and reproducibility
The data for validating the HPLC assay are shown in
Tables 1–3. The recovery was higher than 84% (Table 1),
the intra-daily variation was lower than 4.22% (Table 2) and
the inter-daily variation lower than 7.69% (Table 3).
3.4. Determination of paeoniﬂorin blood plasma of rats
Fig. 4 shows that, after oral co-administration of paeoni-
florin and sinomenine hydrochloride, plasma levels of
paeoniflorin were significantly increased with a Cmax of
13.7g/ml.
3.5. Kinetic analysis
As calculated from plasma concentrations of paeoni-
florin following oral administration of paeoniflorin aloneethods. Relative bioavailability (Fref) of paeoniflorin was
alculated using the following formula:
(%) = AUC0−∞(A)
AUC0−∞(B)
× 100
here AUC0–∞(A) represents the area under the
oncentration–time curve from zero up to infinite time
hen paeoniflorin and sinomenine were given jointly and
UC0–∞(B) represents the area when paeoniflorin was given
lone.
. Results
.1. HPLC chromatograms
The HPLC chromatograms of blank plasma, plasma
piked with paeoniflorin (4.73g/ml) and the plasma ob-
ained at 45 min after oral co-administration of paeoniflorin
lus sinomenine together, derived as explained above, are
hown in Fig. 3. The retention time of paeoniflorin was
ound to be around 19.1 min. No interfering peaks were
bserved within the time frame in which paeoniflorin was
etected.
.2. Calibration curve
The calibration curve for area ratio of paeoniflorin to pen-
oxifylline was linear (r2 = 0.99997) over the range of concen-
rations of 0.15–7.10g/ml. With the least-squares method,
regression equation of Y= 1.12643 X+ 0.00135 (X is the
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Table 1
Recovery of the paeoniflorin assay
Test no. Spiked concentration (g/ml) Measured value (g/ml)a Recovery (%)b R.S.D. (%)
1 7.10 6.81± 0.14 95.92 2.11
2 4.73 4.62± 0.09 97.67 2.01
3 0.59 0.50± 0.03 84.75 6.00
4 0.15 0.14± 0.01 97.77 10.41
a Data are expressed as mean±S.D. (n= 3).
b Recovery denotes the ratio of measured value over spiked concentration.
Table 2
Precision of the intra-daily assay
Test no. Spiked concentration (g/ml) Calculated concentration (g/ml) Measured value (g/ml)a Precision (%)b R.S.D. (%)
0 h 5 h 15 h
1 7.10 6.78 7.01 6.93 6.91± 0.12 97.32 1.69
2 4.73 4.65 4.56 4.68 4.63± 0.06 97.89 1.35
3 0.59 0.56 0.52 0.55 0.54± 0.02 91.53 3.83
4 0.15 0.14 0.14 0.13 0.14± 0.01 93.33 4.22
a Data are expressed as mean±S.D. (n= 3).
b Precision denotes the ratio of measured value over spiked concentration.
Table 3
Precision of the inter-daily assay
Test no. Spiked concentration (g/ml) Treated concentration (g/ml) Measured value (g/ml)a Precision (%)b R.S.D. (%)
Day 1 Day 2 Day 3
1 7.10 6.78 6.89 7.05 6.91± 0.14 97.28 1.97
2 4.73 4.65 4.66 4.72 4.68± 0.04 98.87 0.81
3 0.59 0.56 0.59 0.55 0.57± 0.02 96.05 3.67
4 0.15 0.14 0.13 0.12 0.13± 0.01 86.67 7.69
a Data are expressed as mean±S.D. (n= 3).
b Precision denotes the ratio of measured value over spiked concentration.
or co-administration with sinomenine hydrochloride to the
rats (n= 6, each group), the pharmacokinetic parameters
of paeoniflorin are presented in Table 4. Computation of
pharmacokinetic parameters using PK solutions 2.0 soft-
ware (www.summitpk.com) showed that many parameters
(i.e. tmax, Cmax, AUC, t1/2, CL and Vd) were dramatically
altered by co-administration of paeoniflorin plus sinome-
Fig. 4. Plasma concentration–time curve of paeoniflorin. ( ): A plasma
concentration–time curve of paeoniflorin in a representative rat after oral co-
administration with paeoniflorin (150 mg/kg) plus sinomenine hydrochlo-
ride (90 mg/kg) and (	): a plasma concentration–time curve of paeoni-
florin in a representative rat after oral administration of paeoniflorin alone
(150 mg/kg).
nine in comparison with administration of paeoniflorin alone.
These results suggest that the pharmacokinetics of the inter-
actions between paeoniflorin and sinomenine might be quite
complex.
4. Discussion
Pharmacokinetics aims to characterize drug adsorption,
distribution, metabolism and excretion, and it is used in the
clinical setting to design safe and effective protocols for drug
administration. Data and information obtained from pharma-
cokinetic studies on active compounds of medicinal herbs
could help us to understand the complex action of Chinese
herbal medicines and to predict a variety of events related
to efficacy and toxicity of herbs and herbal preparations (De
Smet and Rivier, 1989; De Smet and Brouwers, 1997). More-
over, pharmacokinetic studies of new herbal products could
be extremely important as a means to design the most effec-
tive therapeutic dosing regimes.
A simple and rapid analytical method is needed for the
pharmacokinetic evaluation of paeoniflorin. Our approach to
this problem was to use the HPLC method to analyze the
concentrations of paeoniflorin in rat’s plasma. The validation
results showed the R.S.D. of accuracy and precision of the
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Table 4
PK parameters of paeoniflorin after oral administration of paeoniflorin
alone (150 mg/kg) or co-administration of paeoniflorin with sinomenine hy-
drochloride (90 mg/kg) to rats (n= 6)
Pharmacokinetic
parametersa
Paeoniflorin aloneb Paeoniflorin plus
sinomenineb
tmax (min) 45.00± 5.00 77.30± 17.50c
Cmax (g/ml) 1.26± 0.23 6.03± 2.45c
AUC0–t (g min/ml) 116.68± 37.54 1528.27± 555.07d
AUC0–∞ (g min/ml) 124.62± 36.91 1540.43± 548.96d
t1/2 E phase (min) 55.07± 24.91 84.14± 53.11
t1/2 D/A phase (min) 19.58± 9.01 53.78± 22.17e
t1/2 A phase (min) 17.63± 11.62 44.70± 10.26e
CL (ml min/kg) 1301.83± 429.03 110.44± 45.61c
Vd (ml/kg) 102044.14± 46608.43 16064.25± 17189.33e
MRT (min) 133.12± 38.63 224.07± 26.62c
Frel (%) N/a 12.36
a Cmax, maximum plasma concentration; tmax, time to reach maximum
plasma concentration; AUC0–t, area under the concentration–time curve
from zero up to a definite time t; AUC0–∞, area under the concentration–time
curve from zero up to infinite time; t1/2 E phase, half-life of elimination phase;
t1/2 D/A phase, half-life of distribution phase; t1/2 A phase, half-life of absorption
phase; Vd, volume of distribution; CL, total clearance; MRT, mean residence
time and Frel, relative bioavailability.
b Data are expressed as mean±S.D.
c Values are significantly different from that of the paeoniflorin alone group
by Student’s t-test at P< 0.01.
d Values are significantly different from that of the paeoniflorin alone group
by Student’s t-test at P< 0.001.
e Values are significantly different from that of the paeoniflorin alone group
by Student’s t-test at P< 0.05.
paeoniflorin calibration curve were less than 10%, R.S.D.
of intra-daily and inter-daily assay were also less than 10%,
and the recovery rates were higher than 80%. The results
indicated that the HPLC assays used in the present study have
good reproducibility, accuracy and precision; they could be
successfully applied for the quantitative assay of paeoniflorin
in rat blood samples.
In previous reports, the biosamples were obtained by pre-
cipitating protein with acetonitrile and extracting with ether
to remove non-polar interfering impurities. This is a cumber-
some, complex process resulting in rather lower recoveries
and involving the use of toxic solvents (Chen et al., 1999;
Guan et al., 2003). In our method, 4.5% perchloric acid aque-
ous solution was used to denature the plasma protein (Keung
et al., 1996). The results of method validation, particularly
the recoveries, precision and reproducibility, indicate that the
processes for denaturing plasma protein are simple, quick and
convenient.
The results of AUC0–t of pharmacokinetics obtained in
the study demonstrate that oral bioavailability of paeoniflorin
was elevated by more than 12 times in rats treated with co-
administration of sinomenine at the tested doses that are com-
parable to the doses of these two herbs used in clinical for-
mulas for the treatment of rheumatoid arthritis.
Compared with those of paeoniflorin given alone, the phar-
m
i
n
differences. The results indicate that sinomenine hydrochlo-
ride at a dosage of 90 mg/kg can markedly elevate the plasma
concentration, delay the peak time and consequently increase
the bioavailability of paeoniflorin in rats. However, the mech-
anism of sinomenine on enhancement of the bioavailability of
paeoniflorin in rats remains unclear. There are many reports in
the literature that support the hypothesis that P-glycoprotein
inhibitors enhance drug absorption from the intestine, elevat-
ing the bioavailability of the drug (Barthe et al., 1999; Bouer
et al., 1999). Previous studies show that sinomenine is a po-
tent inhibitor of immunity (Vieregge et al., 1999), and that its
excretion is regulated by P-glycoprotein (Tsai and Wu, 2003);
hence, it is possible that sinomenine can alter the disposition,
absorption and bioavailability of paeoniflorin. Our prelimi-
nary experimental data using a model of rat everted intestinal
sacs (Bouer et al., 1999) showed that sinomenine could act
as a P-glycoprotein inhibitor, and therefore promote the in-
testinal transportation of drug from mucosa to serosa, this
implied that the enhanced bioavailability of paeoniflorin by
the co-administration of sinomenine might be closely related
to P-glycoprotein (data not shown).
5. Conclusion
In the present study, an HPLC method has been devel-
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Cacokinetic parameters of paeoniflorin can be dramatically
mproved by the concomitant administration with sinome-
ine; AUC,Cmax,Vd and MRT, especially, showed significantped and validated for the characterization of plasma, and a
ugular-catheterized rat model has been established to inves-
igate the influences of co-administration of sinomenine on
he pharmacokinetics of paeoniflorin in freely moving rats.
he results show that sinomenine hydrochloride enhanced the
lasma concentration and extended the disposition time for
aeoniflorin resulting in a marked increase of bioavailability
n rats.
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